|
Study | Study design | Animals | Animal number | Modeling method | Treatment groups | Main outcomes | Courses |
|
Kassel et al. [12] | Unclear | C57BL/6 | Unclear | Western diet (40% kcal from milk fat), NAFLD | Vehicle pumps and argatroban pumps | Antifibrotic effect | 23 weeks |
Li et al. [13] | Unclear | Sprague-Dawley rats | 52 | CCl4/porcine serum, hepatic fibrosis | Normal control, CCl4, porcine serum, CCl4 + LAAH, and porcine serum + LAAH | Liver function tests, and area of collagens | 10 weeks |
Lee et al. [16] | Unclear | Sprague-Dawley rats | 24 | 1% DMN, hepatic fibrosis | Control, DMN, DMN + LH, and DMN + LHP | Antifibrotic effect | 4 weeks |
Vilaseca et al. [17] | Randomized controlled study | Wistar rats, Sprague-Dawley rats | Unclear | CCl4/TAA, cirrhosis | Rivaroxaban and vehicle | Antifibrotic effects, HSC activation, and portal pressure | 18 weeks |
Cerini et al. [21] | Randomized controlled study | Wistar rats and Sprague-Dawley rats | Unclear | CCl4/TAA, cirrhosis | Enoxaparin and vehicle | Antifibrotic effect and inflammation response | 15 weeks |
Fortea et al. [22] | Unclear | Sprague-Dawley rats | Unclear | CCl4, cirrhosis | Saline, CCl4 + Saline, and CCl4 + enoxaparin | Survival, liver function tests, antifibrotic effect, and inflammation response | 12 weeks |
Assy et al. [28] | Unclear | Sprague-Dawley rats | 28 | TAA, hepatic cirrhosis | Controls, aspirin, and enoxaparin | Survival, liver function tests, and antifibrotic effect fibrosis | 5 weeks |
Li et al. [29] | Randomized controlled study | Sprague-Dawley rats | 45 | TAA, hepatic fibrosis | TAA, TAA + low-dose aspirin, TAA + high-dose aspirin, and TAA + enoxaparin | Liver function tests and antifibrotic effect | 4 weeks |
Yan et al. [30] | Randomized controlled study | C57BL/6 | Unclear | CCl4, cirrhosis | Different groups of the enzymatically depolymerized heparins and saline | Liver function tests, antifibrotic effect, and inflammation response | 8 weeks |
Fujita et al. [31] | Randomized controlled study | Fischer rats | 344 | A CDAA diet or an HF/HC diet, NAFLD | CDAA, CDAA + aspirin, CDAA + ticlopidine, CDAA + cilostazol, CSAA | Antifibrotic effect and inflammation response | 16 weeks |
Abdel-Salam et al. [32] | Randomized controlled study | Sprague-Dawley rats | 48 | Bile duct ligated (BDL), cholestatic liver injury | Sham, BDL, BDL + UFH, BDL + nadroparin, BDL + tinzaparin, and BDL + enoxaparin | Liver function tests | 3 weeks |
Abe et al. [33] | Unclear | Wistar rats | Unclear | CCl4, hepatic fibrosis | CCl4 and CCl4 + dalteparin | Antifibrotic effect | 7 weeks |
Lee et al. [34] | Unclear | Sprague-Dawley rats | 24 | TAA, hepatic fibrosis | Saline, and dabigatran etexilate | Liver function tests, antifibrotic effect, fibrin deposition, intrahepatic angiogenesis, and portal hypertension | 12 weeks |
Mahmoud et al. [35] | Randomized controlled study | Albino rats | 24 | CCl4, hepatic fibrosis | Control group, CCl4, and CCl4 + rivaroxaban | Liver function tests, antifibrotic effect, and inflammation response | 6 weeks |
Mahmoud et al. [36] | Randomized controlled study | Albino rats | 56 | CCl4, hepatic fibrosis | Normal control, fibrosis control, dabigatran-treated, and clopidogrel-treated group | Liver function tests, antifibrotic effect, and inflammation response | 6 weeks |
Liu et al. [37] | Unclear | Sprague-Dawley rats | 27 | CCl4, hepatic fibrosis | Control group, CCl4, and CCl4 + aspirin | Liver function tests, antifibrotic effect, and inflammation response | 6 weeks |
|